AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2025

Oct 29, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2025-10-27

Reporting Person: Gheuens Sarah (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-10-27	Common stock	M	3302	$25.01	Acquired	65029	Direct
2025-10-27	Common stock	S	3302	$43.92	Disposed	61727	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-10-27	Stock options (right to buy)	$25.01	M	3302	Disposed	2033-03-01	Common stock (3302)	Direct

Footnotes

F1: Includes 456 shares purchased through the Company's employee stock purchase plan.

F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $43.77 to $44.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.